GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (LTS:0LER) » Definitions » Long-Term Debt

Teva Pharmaceutical Industries (LTS:0LER) Long-Term Debt : $16,400 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Teva Pharmaceutical Industries Long-Term Debt?

Teva Pharmaceutical Industries's Long-Term Debt for the quarter that ended in Sep. 2024 was $16,400 Mil.

Teva Pharmaceutical Industries's quarterly Long-Term Debt declined from Mar. 2024 ($16,584 Mil) to Jun. 2024 ($16,547 Mil) and declined from Jun. 2024 ($16,547 Mil) to Sep. 2024 ($16,400 Mil).

Teva Pharmaceutical Industries's annual Long-Term Debt declined from Dec. 2021 ($21,617 Mil) to Dec. 2022 ($19,103 Mil) and declined from Dec. 2022 ($19,103 Mil) to Dec. 2023 ($18,161 Mil).


Teva Pharmaceutical Industries Long-Term Debt Historical Data

The historical data trend for Teva Pharmaceutical Industries's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Long-Term Debt Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24,562.00 22,731.00 21,617.00 19,103.00 18,161.00

Teva Pharmaceutical Industries Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,495.00 18,161.00 16,584.00 16,547.00 16,400.00

Teva Pharmaceutical Industries  (LTS:0LER) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Teva Pharmaceutical Industries Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Headlines

No Headlines